Therefore, to test the hypothesis whether MYL9 act on CRC via the CCL2/TGFβ1/PI3K/AKT axis, CRC cells were treated with recombinant CCL2 (20 ng/mL), TGF-β1 (0.1 ng/mL), and PI3K-AKT pathway inhibitors LY294002 (0.5 ug/mL). This evidence concerns the gene MYL9 and colorectal carcinoma.